All In Biotech

Drug Trial Radar · NCT02770807

Intra-Erythrocyte Dexamethasone Sodium Phosphate in Ataxia Telangiectasia Patients

Multi-center, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Effects of Intra-Erythrocyte Dexamethasone Sodium Phosphate on Neurological Symptoms in Patients With Ataxia Telangiectasia

Last checked: Nov 19, 2026Latest source record: May 10, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 176 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

176

Actual

Start

Mar 2, 2017

Primary completion

May 13, 2021

Study completion May 13, 2021

Sponsor

Lead sponsor
Quince Therapeutics S.p.A.Industry
Sponsor type
Industry
First posted
May 12, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 6 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Objectives: The objective of study was to evaluate the safety and the efficacy of EryDex (Dexamethasone sodium phosphate encapsulated in autologous erythrocytes, using the EryDex System - EDS) at two dose levels (low dose and high dose DSP/infusion), compared to placebo, on Neurological Symptoms in Patients With Ataxia Telangiectasia. Initial Double-Blind Treatment Period (0 to 6 Months) Primary Efficacy Objective: • Evaluate the effect of EryDex at two dose levels (low dose and high dose DSP/infusion), compared to placebo, on central nervous system (CNS) symptoms measured by the change in the Modified International Cooperative Ataxia Rating Scale (mICARS) from baseline to Month 6 (Visit 9) in patients with ataxia telangiectasia (A-T). Secondary Efficacy Objectives: * Evaluate the effect of EryDex, compared to placebo, on the Clinical Global Impression of Change (CGI-C) in patients with A-T from baseline to Month 6 (Visit 9). * Evaluate the effect of EryDex, compared to placebo, on measures of Clinical Global Impression of Severity (CGI-S; structured) in patients with A-T from baseline to Month 6 (Visit 9) * Evaluate the effect of EryDex, compared to placebo, on measures of Adaptive behavior measures in patients with A-T by the Vineland Adaptive Behavior Scales (VABS) from baseline to Month 6 (Visit 9). Safety Objectives: • Evaluate the safety and tolerability of two non-overlapping doses of EryDex, compared to placebo, in patients with A-T over the 12-month double-blind study duration. Extension Treatment Period (6-12 Months): Primary Objective: • Evaluate the efficacy of EryDex at two dose levels (low dose and high dose DSP/infusion) compared to placebo, in treating CNS symptoms in A-T patients during longer-term treatment (up to 12 months), as measured by the mICARS. Secondary Objectives: * Evaluate the longer-term (up to 12 months) safety and tolerability of EryDex in A-T patients. * Compare the effects of EryDex on the CGI-C and CGI-S (structured), VABS, and QoL using the EQ-5D-5L scale.

Conditions

  • Nervous System Disease
  • Genetic Syndrome

Interventions

  • EryDex Low dose DSPDrug

    EDS-EP dose range of \~5-10 mg DSP/infusion

  • EryDex High dose DSPDrug

    EDS-EP dose range of \~14-22 mg DSP/infusion

  • Pooled PlaceboDrug

    EDS processed autologous erythrocytes using a sodium chloride \[NaCl\] solution.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Modified International Cooperative Ataxia Rating Scale (mICARS)Time frame: to Month 6 (Visit 9)

Locations

22 sites in 12 countries. Site status is shown where the registry gives one.

  • UCLA-Ataxia Center and HD Center of Exellence

    Los Angeles, California

  • The Ataxia-Telangiectasia Clinical Center, The Johns Hopkins Hospital

    Baltimore, Maryland

  • Cincinnati Children's Hospital Medical Center

    Cincinnati, Ohio

  • UT Health

    Houston, Texas

  • Royal Children's Hospital

    Melbourne, Victoria, Australia

  • Laboratoriumgeneeskunde

    Leuven, Belgium

  • Klinik für Kinder- und Jugendmedizin Pädiatrische Allergologie, Pneumologie und Mukoviszidose, Universitätsklinikum Frankfurt

    Frankfurt am Main, Hesse, Germany

  • All India Institute of Medical Sciences

    New Delhi, India

  • National Institute of Mental Health and Neurosciences

    Bangalore, Karnataka, India

  • Amrita Institute of Medical Sciences and Research Centre

    Kochi, Kerala, India

  • Jaslok Hospital and Research Centre

    Mumbai, Maharashtra, India

  • PD Hinduja National Hospital and Medical Research

    Mahīm, Mumbai, India

  • Vijaya Health Centre, Department of Neurology

    Chennai, Tamil Nadu, India

  • Nizam's Institute of Medical Sciences

    Hyderabad, Telangana, India

  • Sheba Medical Center

    Tel HaShomer, Israel

  • U.O. Neurologia e Psichiatria dell'Infanzia e dell' Adolescenza. ASST Spedali Civili, Piazzale Spedali Civili, 1

    Brescia, Italy

  • Dipartimento di Pediatria e Neuropsichiatria Infantile, Università Sapienza di Roma, Azienda Policlinico Universitario Umberto I

    Rome, Italy

  • Norwegian National Unit for Newborn Screening, Division of Pediatric and Adolescent Medicine, Oslo University Hospital

    Oslo, Norway

  • Department of Clinical Immunology The Children's Memorial Health Institute

    Warsaw, Poland

  • Hospital Universitario La Paz.

    Madrid, Spain

  • El Razi Hospital

    Manouba, Tunisia

  • Nottingham University Hospitals NHS Trust - Queen's Medical Centre

    Nottingham, Nottinghamshire, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.